Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

VGX-3100 is an investigational DNA-based immunotherapy being developed as an alternative to surgery and ablation for cervical High-Grade Squamous Intraepithelial Lesion (HSIL) with the aim of preserving reproductive health while treating precancerous disease. Response durability up to 1.5 y followin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bhuyan, Prakash K., Dallas, Michael, Kraynyak, Kim, Herring, Timothy, Morrow, Matthew, Boyer, Jean, Duff, Susan, Kim, Joseph, Weiner, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078703/
https://www.ncbi.nlm.nih.gov/pubmed/33175656
http://dx.doi.org/10.1080/21645515.2020.1823778

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8078703/
https://www.ncbi.nlm.nih.gov/pubmed/33175656
http://dx.doi.org/10.1080/21645515.2020.1823778

Ejemplares similares